Mon - Fri: 08:00AM - 20:00PM

Saturday and Sunday - CLOSED

+ 0800 2466 7921

Contact Us For Help

34th Avenue

New York, W2 3XE

Frontier Diagnostics

Better Diagnostics Saves Lives

Introducing CTC Liquid biopsy breast
cancer clinical trial.

Latest Updates in Cancer Testing

Early detection can improve survival rates by up to 90%. Schedule your test today!

About Us.

Better Diagnostics Saves Lives

The mission and passion of Frontier Diagnostics is to advance healthcare and personalized medicine by creating technologies and products that help uncover the biological complexities of health and disease at the level of each single cell.

Better Diagnostics Saves Lives

Our highest priority is to improve diagnostic and therapeutic approaches to human health. CTC liquid biopsy offeres detection and analysis of important, but rare, cells associated with disease.

Better Diagnostics Saves Lives

The CELLTRAK® CTC Trial

The first and only clinical trial seeking FDA-clearance, a blood test for enumerating circulating tumor cells (CTCs). CTCs are cancer cells that detach from a primary tumor and travel through the bloodstream or lymphatic system to other parts of the body.

Revolutionary Liquid Biopsy Technology

A “liquid biopsy” that can be used at any time during a patient’s course of disease. Performed at our Head Laboratories in Germany. This trial will be processed using the CELLSTRAK® Circulating Tumor Cell System

Our team

Our team of Doctors, consultants, medical advisory board are here to help, the current medical guidelines are in need of review and CTC can help women have peace of mind via better diagnostics and non invasive biopsy

Together Defeating Cancer

Better Diagnostics Saves Lives

The CELLTRAK® CTC trial is a simple, actionable blood test that helps oncologists assess the prognosis of patients with metastatic breast, prostate* , or colorectal cancer. 

Sport&Science

As an adjunct to standard methods of monitoring, the CELLTRAK® CTC Test provides:

An early assessment of patient prognosis Detection of changes in prognosis at any time The most accurate assessment of prognosis in cases where CTC and imaging are discordant in patients with metastatic breast cancer, and in cases where CTC and PSA are discordant in patients with metastatic prostate cancer

References:

Cristofanilli M, Hayes DF, Budd GT, et al. J Clin Oncol. 2005;23(7):1420-1430. 
de Bono JS, Scher HI, Montgomery RB, et al. Clin Cancer Res. 2008;14:6302-6309.
Cohen SJ, Punt CJA, Iannotti N, et al. J Clin Oncol. 2008;26(19):3213-3221.

Frontier Diagnostics supports a healthy active lifestyle via international sports sponsorship events: sport can cut risk of illness by over 50%

Information for Oncologists

CTCs are a strong, independent predictor of overall and progression-free survival in metastatic breast, prostate* and colorectal cancer
Use the CELLTRAK ® CTC Test to inform clinical decisions in patients with metastatic breast, prostate* and colorectal cancerat any time during the course of disease

Start testing patients

Clinical studies validate the predictive accuracy of the CELLTRAK system, if you wish to learn more or recommend patients for the trials please contact:
info@frontierdiagnostics.net

Your Journey to Early Detection, Step by Step.

Understanding the testing process can ease your concerns and help you prepare. Here’s what to expect when you choose [Your Company Name] for your cancer testing needs:

Consultation

Meet with our specialists to discuss your health history and concerns

Personalized Testing Plan

Based on your needs, we’ll recommend the most suitable tests to detect any signs of cancer.

Testing

Our cutting-edge technology ensures that your tests are performed with precision and care.

Results & Next Steps

Our team will explain your results in detail and guide you through any follow-up steps or treatments if necessary.